Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 5/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | ECE1 | P42892 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12173943 | 0.84 | SMN1; SMN2 (0.53) | SMN1; SMN2TP53ALDH1A1TDP1HPGD | |
| SCHEMBL18908668 | 0.84 | SMN1; SMN2 (0.59) | SMN1; SMN2TP53ALDH1A1TDP1HPGD | |
| SCHEMBL24711403 | 0.83 | ECE1 (0.52) | SMN1; SMN2TP53ALDH1A1HPGDKMT2A | |
| SCHEMBL23179898 | 0.82 | ALDH1A1 (0.38) | SMN1; SMN2TP53ALDH1A1TDP1HPGD | |
| SCHEMBL11912088 | 0.81 | SMN1; SMN2 (0.49) | SMN1; SMN2TP53ALDH1A1TDP1HPGD | |
| SCHEMBL24760200 | 0.81 | ALDH1A1 (0.55) | ALDH1A1TDP1HPGDHTT | |
| SCHEMBL12587348 | 0.80 | SMN1; SMN2 (0.45) | SMN1; SMN2TP53ALDH1A1TDP1HPGD | |
| SCHEMBL19116931 | 0.80 | TP53 (0.52) | SMN1; SMN2TP53ALDH1A1TDP1HPGD | |
| SCHEMBL20340484 | 0.79 | SMN1; SMN2 (0.66) | SMN1; SMN2TP53ALDH1A1TDP1HPGD | |
| SCHEMBL18199495 | 0.79 | SMN1; SMN2 (0.66) | SMN1; SMN2TP53ALDH1A1TDP1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-09 | — | — | US | disclosed |
| US-20170233405-A1 | MAX BINDERS AS MYC MODULATORS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2017-08-17 | — | — | US | disclosed |
| EP-2686019-B1 | CONJUGATED MOLECULES COMPRISING A PEPTIDE DERIVED FROM THE CD4 RECEPTOR COUPLED TO A POLYANIONIC POLYPEPTIDE FOR THE TREATMENT OF AIDS | PASTEUR INSTITUT (FR) | 2017-03-01 | — | — | EP | disclosed |
| EP-2249873-B1 | CONJUGATED MOLECULES COMPRISING A PEPTIDE DERIVED FROM THE CD4 RECEPTOR COUPLED TO A POLYANION FOR THE TREATMENT OF AIDS | PASTEUR INSTITUT (FR) | 2016-11-16 | — | — | EP | disclosed |
| US-9163227-B2 | Anti-diabetic compounds | COVX TECHNOLOGIES IRELAND LIMITED (IE) | 2015-10-20 | — | — | US | disclosed |
| US-20130164310-A1 | ANTI-DIABETIC COMPOUNDS | COVX TECHNOLOGIES IRELAND LIMITED | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | SMN1; SMN2 2633/4885TP53 503/4885ALDH1A1 4236/4885 |
| US-20170233405-A1 | MAX BINDERS AS MYC MODULATORS AND USES THEREOF | MYC, MYCBP, MYCBP2 | SMN1; SMN2 4044/4885TP53 57/4885ALDH1A1 3226/4885 |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | SMN1; SMN2 2633/4885TP53 503/4885ALDH1A1 4236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.